dc.creator | Karavasilis, V. | en |
dc.creator | Kosmidis, P. | en |
dc.creator | Syrigos, K. N. | en |
dc.creator | Mavropoulou, P. | en |
dc.creator | Dimopoulos, M. A. | en |
dc.creator | Kotoula, V. | en |
dc.creator | Pectasides, D. | en |
dc.creator | Boukovinas, I. | en |
dc.creator | Klouvas, G. | en |
dc.creator | Kalogera-Fountzila, A. | en |
dc.creator | Papandreou, C. N. | en |
dc.creator | Fountzilas, G. | en |
dc.creator | Briasoulis, E. | en |
dc.date.accessioned | 2015-11-23T10:33:36Z | |
dc.date.available | 2015-11-23T10:33:36Z | |
dc.date.issued | 2014 | |
dc.identifier.issn | 0250-7005 | |
dc.identifier.uri | http://hdl.handle.net/11615/29125 | |
dc.description.abstract | Aim: To determine the more effective dosing sequence of intermittent erlotinib and docetaxel for treating chemotherapy-naive patients with advanced Non-Small Cell Lung Cancer (NSCLC). Patients and Methods: Patients were randomized to receive daily erlotinib for 12 consecutive days prior to docetaxel (Arm A) or after docetaxel (Arm B). Progression-free survival (PP'S) was the primary end-point; secondary end-points were overall survival (OS) and objective response rate (ORR). Results: Fifty eligible patients received a total of 226 treatment cycles (median: 3). Median PFS and OS were 3.6 months and 10.5 months, respectively (differences were not statistically significant between the two arms). Neutropenia grade 3 and 4 occurred in 15 patients, while two patients developed grade 3 diarrhea. There were two treatment-related deaths (pulmonary embolism and non-neutropenic sepsis). Conclusion: intermittent administration of erlotinib does not appear to improve the clinical outcome of single-agent docetaxel chemotherapy in unselected patients with NSCLC in the first-line setting. | en |
dc.source.uri | <Go to ISI>://WOS:000343139500055 | |
dc.subject | Erlotinib | en |
dc.subject | docetaxel | en |
dc.subject | non-small cell lung cancer | en |
dc.subject | TYROSINE KINASE INHIBITORS | en |
dc.subject | RANDOMIZED-TRIAL | en |
dc.subject | FORMER SMOKERS | en |
dc.subject | CHEMOTHERAPY | en |
dc.subject | PACLITAXEL | en |
dc.subject | CARBOPLATIN | en |
dc.subject | GEMCITABINE | en |
dc.subject | EFFICACY | en |
dc.subject | THERAPY | en |
dc.subject | Oncology | en |
dc.title | Docetaxel and Intermittent Erlotinib in Patients with Metastatic Non-small Cell Lung Cancer; A Phase II Study From The Hellenic Cooperative Oncology Group | en |
dc.type | journalArticle | en |